Should You Buy Merus NV (MRUS) Stock on Wednesday?

Overall market sentiment has been high on Merus NV (MRUS) stock lately. MRUS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Merus NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MRUS!

See Full MRUS Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With MRUS Stock Today?

Merus NV (MRUS) stock is lower by -3.22% while the S&P 500 is up 0.86% as of 12:53 PM on Wednesday, Mar 6. MRUS is lower by -$1.61 from the previous closing price of $49.97 on volume of 467,111 shares. Over the past year the S&P 500 is up 26.53% while MRUS is up 151.35%. MRUS lost -$3.00 per share in the over the last 12 months. To screen for more stocks like Merus NV click here.

More About Merus NV

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Click Here to get the full Stock Report for Merus NV stock.